vinorelbine pierre fabre
pierre fabre medicament australia pty ltd - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg - soft gelatin capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg excipient: edible ink red ethanol gelatin glycerol anidrisorb 85/70 85% phosal 53 mct iron oxide red macrogol 400 medium-chain triglycerides purified water titanium dioxide
navelbine
new zealand medical & scientific ltd - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg - soft gelatin capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg excipient: edible ink red ethanol gelatin glycerol anidrisorb 85/70 85% phosal 53 mct iron oxide red macrogol 400 medium-chain triglycerides purified water titanium dioxide - first line treatment of advanced non-small cell lung cancer (nsclc) as a single agent or in combination
vinorelbine te arai
te arai biofarma limited - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30mg; - capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30mg excipient: gelatin iron oxide red macrogol 400 polysorbate 80 purified water sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
navelbine oral vinorelbine 30mg (as tartrate) capsule blister pack
pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
vinorelbine pierre fabre vinorelbine 30mg (as tartrate) capsule blister pack
pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
vinorelbine lrx vinorelbine (as tartrate) 30 mg soft capsules blister pack
luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: polysorbate 80; titanium dioxide; iron oxide red; purified water; macrogol 400; partially dehydrated liquid sorbitol; gelatin - non-small cell lung cancer: vinorelbine lrx is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lrx is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
vinorelbine lu vinorelbine (as tartrate) 30 mg soft capsules blister pack
luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; iron oxide red; partially dehydrated liquid sorbitol; titanium dioxide; macrogol 400; purified water; polysorbate 80 - non-small cell lung cancer: vinorelbine lu is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lu is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
velabine vinorelbine (as tartrate) 30 mg soft capsules blister pack
luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; partially dehydrated liquid sorbitol; polysorbate 80; macrogol 400; titanium dioxide; purified water; iron oxide red - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
vinorelbine- vinorelbine injection, solution
hospira, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - vinorelbine injection, usp is indicated: none pregnancy category d risk summary vinorelbine can cause fetal harm when administered to a pregnant woman. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus. animal data in a mouse embryofetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m2 (approximately 0.18 times the recommended human dose based on body surface area) or greater. at doses t
vinorelbine lotus 20 mg soft capsule
lotus support services s.r.l. 47 theodor pallady blvd. 2nd office, entrance b, 1st floor 3rd district bucharest, romania - vinorelbine tartrate - soft capsule - vinorelbine tartrate 20 mg - antineoplastic agents